[4-(4-Fluorophenyl)Sulfonylpiperazin-1-Yl]-[4-[[7-(Trifluoromethyl)Quinolin-4-Yl]Amino]Phenyl]Methanone

CAS : 72141-57-2

Ref. 3D-FF102650

Informations sur le produit

• Nom: [4-(4-Fluorophenyl)Sulfonylpiperazin-1-Yl]-[4-[[7-(Trifluoromethyl)Quinolin-4-Yl]Amino]Phenyl]Methanone
• Synonymes: Piperazine, 1-((4-fluorophenyl)sulfonyl)-4-(4-((7-(trifluoromethyl)-4-quinolinyl)amino)benzoyl)-, 1-((4-Fluorophenyl)sulfonyl)-4-(4-((7-(trifluoromethyl)-4-quinolinyl)amino)benzoyl)piperazine, Brn 6257178, Losulazina, Losulazina [Spanish], Losulazinum, Losulazinum [Latin], {4-[(4-Fluorophenyl)Sulfonyl]Piperazin-1-Yl}(4-{[7-(Trifluoromethyl)Quinolin-4-Yl]Amino}Phenyl)Methanone

Description

[4-(4-Fluorophenyl)Sulfonylpiperazin-1-Yl]-[4-[[7-(Trifluoromethyl)Quinolin-4-Yl]Amino]Phenyl]Methanone (LAP) is a novel α2β3 antagonist that inhibits the angiotensin system. It has been shown to be effective at inhibiting the release of dopamine from rat primary hepatocytes and has no effect on the release of norepinephrine. This drug also blocks the binding of angiotensin II to its receptors, which results in decreased blood pressure and increased urine output. LAP is currently in clinical trials for testing its efficacy in treating heart failure.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 558.55 g/mol
• Formule: C₂₇H₂₂F₄N₄O₃S
• Degré de pureté: Min. 95%